Skip to main content
. 2021 Feb 28;70(10):2805–2817. doi: 10.1007/s00262-021-02882-y

Fig. 4.

Fig. 4

LH/FSH ratio at landmark of 6/8 weeks is associated with therapy response for the male but not for the female population. Therapy response was defined as SD, PR, CR by RECIST in monitoring CT after 12 weeks of treatment with nivolumab. The bar graph is showing mean ± SD. * p < 0.05; ** p < 0.01; *** p < 0.001